SARS-CoV-2 Mutations Responsible for Immune Evasion Leading to Breakthrough Infection.
b.1.617.2 (delta-variant)
breakthrough infection
covid-19 retro
immune evasion
next genome sequencing
sars-cov-2
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
accepted:
24
09
2022
entrez:
31
10
2022
pubmed:
1
11
2022
medline:
1
11
2022
Statut:
epublish
Résumé
India had faced a devastating second outbreak of COVID-19 infection, in which a majority of the viral sequences were found to be of the B.1.617.2 lineage (Delta-variant). While India and the world focused on vaccination, reports of vaccine-immunity evasion by the virus, termed "breakthrough cases", emerged worldwide. Our study was focused on the primary objective to identify the mutations associated with breakthrough infections SARS-CoV-2. In our study, we extracted the SARS-CoV-2 RNA (ribonucleic acid) from reverse transcription-polymerase chain reaction (RT-PCR) positive COVID-19 patients, and 150 random samples were sent for sequencing to the Centre for Cellular & Molecular Biology, Hyderabad. Whole genome sequences of 150 SARS-CoV-2 viral samples were analyzed thoroughly. We mostly found B.1.617 and its sub-lineages in the genomic sequencing results. On further analysis of patient data, it was seen that nine patients had been vaccinated against the SARS-CoV-2 previously. These nine patients had B.1.617/B.1 or A strains, and all of them had similar genomic variations in spike proteins as well as non-structural proteins (NSPs). The mutations seen in these sequences in the Spike (S), NSPs, and open reading frame (ORF) regions would have produced amino acid changes known to improve viral replication, confer drug resistance, influence host-cell interaction, and lead to antigenic drift. Increased virulence culminating in vaccine immunity evasion may be inferred from these specific mutations. Our study adds to the growing body of evidence linking rapidly emerging mutations in the S (Spike) and ORF genes of the SARS-CoV-2 genome to immune evasion.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
India had faced a devastating second outbreak of COVID-19 infection, in which a majority of the viral sequences were found to be of the B.1.617.2 lineage (Delta-variant). While India and the world focused on vaccination, reports of vaccine-immunity evasion by the virus, termed "breakthrough cases", emerged worldwide. Our study was focused on the primary objective to identify the mutations associated with breakthrough infections SARS-CoV-2.
METHODS
METHODS
In our study, we extracted the SARS-CoV-2 RNA (ribonucleic acid) from reverse transcription-polymerase chain reaction (RT-PCR) positive COVID-19 patients, and 150 random samples were sent for sequencing to the Centre for Cellular & Molecular Biology, Hyderabad. Whole genome sequences of 150 SARS-CoV-2 viral samples were analyzed thoroughly. We mostly found B.1.617 and its sub-lineages in the genomic sequencing results.
RESULTS AND INTERPRETATION
CONCLUSIONS
On further analysis of patient data, it was seen that nine patients had been vaccinated against the SARS-CoV-2 previously. These nine patients had B.1.617/B.1 or A strains, and all of them had similar genomic variations in spike proteins as well as non-structural proteins (NSPs). The mutations seen in these sequences in the Spike (S), NSPs, and open reading frame (ORF) regions would have produced amino acid changes known to improve viral replication, confer drug resistance, influence host-cell interaction, and lead to antigenic drift.
CONCLUSIONS
CONCLUSIONS
Increased virulence culminating in vaccine immunity evasion may be inferred from these specific mutations. Our study adds to the growing body of evidence linking rapidly emerging mutations in the S (Spike) and ORF genes of the SARS-CoV-2 genome to immune evasion.
Identifiants
pubmed: 36312656
doi: 10.7759/cureus.29544
pmc: PMC9592688
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e29544Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022, Sahni et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Viruses. 2022 Mar 19;14(3):
pubmed: 35337047
N Engl J Med. 2021 Jun 10;384(23):2212-2218
pubmed: 33882219
Comput Struct Biotechnol J. 2021 Oct 4;:
pubmed: 34630935
Nat Commun. 2019 May 28;10(1):2342
pubmed: 31138817
J Basic Microbiol. 2021 Mar;61(3):180-202
pubmed: 33460172
Sci Immunol. 2021 May 25;6(59):
pubmed: 34035118
J Infect Dis. 2021 Sep 17;224(6):989-994
pubmed: 34260717
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Science. 2020 Sep 4;369(6508):1249-1255
pubmed: 32680882
Cell. 2020 Jul 23;182(2):417-428.e13
pubmed: 32526208
Diabetes Metab Syndr. 2021 May-Jun;15(3):1007-1008
pubmed: 33991805